Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

VITAL trial: Safety of vosaroxin and infusional cytarabine for frontline treatment of AML

ASH 2019

7 - 10 Dec 2019

Published: 27 Jan 2020

Views: 1119

Rating:

Save

Dr Stephen Strickland - Vanderbilt University Medical Center, Nashville, USA

Dr Stephen Strickland speaks to ecancer at the ASH 2019 meeting in Orlando about the VITAL trial of vosaroxin and infusional cytarabine for the frontline treatment of acute myeloid leukaemia (AML).

He explains that the trial focused on a high-risk patient population, including patients who were over 6555years of age or who were 18-54 with high-risk features.

Dr Strickland reports that the combination was reasonably safe and well-tolerated in this patient population. He suggests that it has the potential to replace anthracyclin based induction in the first setting.

Related Videos

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Latest in EGFR mutated NSCLC

Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip

ESMO 2024: Latest in EGFR mutated NSCLC ( Prof Ignacio Gil-Bazo, Dr Mariana Brandão, Prof Benjamin Besse and Prof Enriqueta Felip )

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

More from ecancer